A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

NHL Clinical Trial

Official title:

A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05365100
• Other study ID #: BN102-101
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: July 2022
• Est. completion date: July 30, 2024

Study information

• Verified date: March 2023
• Source: BioNova Pharmaceuticals (Shanghai) LTD.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)

Description:

The study is divided into 2 phases. Phase1 dose escalation part will enroll 17-36 patients to evaluate safety and tolerance of BN102 in patients with relapsed/refractory (R/R) CLL/SLL and B-NHL to determine maximum tolerated dose and recommended phase2 dose(RP2D). Phase 2 expansion part will enroll 72-138 patients and be conducted at the selected dose level to further evaluate the safety and tolerability of BN102,as well as preliminary efficacy in specific subtypes of lymphoma. Patients will be allocated into 6 lymphoma subgroup cohorts depends on whether their previous treatment with or without BTK inhibitors. - Cohort 1: patients with mantle cell lymphoma (MCL) previously treated with BTK inhibitors - Cohort 2: patients with MCL who have not previously received a BTK inhibitor - Cohort 3: patients with CLL/SLL who have received prior BTK inhibitors - Cohort 4: patients with CLL/SLL who have not received prior BTK inhibitors - Cohort 5: other B-NHL patients who have received prior BTK inhibitors - Cohort 6: other B-NHL patients who have not received prior BTK inhibitors Patients will receive orally administrated BN102 twice daily under fasting status. Study drug will be administered in 28-day cycles until disease progression or unacceptable toxicity, death, ICF withdraw ect. Subjects may receive study drug in the inpatient or outpatient setting.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 30, 2024
• Est. primary completion date: July 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All of the following conditions must be met for subject enrollment:

• Have fully understood and voluntarily signed the informed consent form ;
• Age = 18 years;
• In phase 1, subjects with histologically confirmed CLL/SLL or B-cell NHL who are relapsed/refractory or intolerable after at least 1 prior line of adequate therapy, and have no better treatment choice as assessed by the investigator;
• In Phase 2, the 6 cohorts had the following specific enrollment criteria and required

further treatment:

• Cohort 1: histologically confirmed MCL, failure or intolerance to at least one prior treatment including BTK inhibitor;
• Cohort 2: histologically confirmed MCL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
• Cohort 3: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
• Cohort 4: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
• Cohort 5: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
• Cohort 6: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
• In addition to CLL and WM, subjects must have at least one radiographically measurable lesion
• ECOG score 0-2;
• Male or female patients of childbearing potential must agree to use effective methods of contraception

Exclusion Criteria:

• Primary central nervous system lymphoma or lymphoma involving the central nervous system;
• Serological status reflects active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection
• HIV infection;
• Abnormalities in hematology lab results
• Cardiac, hepatic, renal, and coagulation abnormalities
• Concomitant clinically significant systemic active infection uncontrollable after appropriate antibiotics or other treatment;
• Expected survival of no more than 24 weeks as judged by the investigator;
• Major surgery within 4 weeks prior to the first dose of study drug
• Required or received anticoagulant therapy (warfarin, or equivalent vitamin K antagonist, or direct thrombin inhibitor, or factor Xa inhibitor, etc.) within 7 days prior to the first dose of study treatment;
• Had undergone cell transplantation or chimeric antigen receptor T cell (CAR-T) therapy within 60 days prior to enrollment
• Combined with uncontrolled active immune cytopenia
• Previous treatment with non-covalently binding BTK inhibitors (e.g. LOXO-305, MK-1026, etc.);
• Pregnant (positive pregnancy test at screening) or lactating female patients;
• QTcF > 450 msec in male patients or QTcF > 470 msec in female patients or other significant ECG abnormalities as judged by the investigator;
• Toxicities due to prior antilymphoma therapy have not stabilized and have not recovered to = Grade 1 (except for clinically insignificant toxicities such as alopecia, etc.);
• History of other malignancies within 5 years prior to enrollment, special cases must be discussed with the medical monitor;
• Prior systemic anti-tumor therapy or investigational therapy received less than 4 weeks or 5 half-lives (whichever is shorter) from the start of the planned study treatment;
• Use of strong CYP3A inhibitors or inducers and proton pump inhibitors within 1 week or 5 half-lives (whichever is shorter) before administration of the first study drug;
• History of acute myocardial infarction, unstable angina, stroke, intracranial hemorrhage or transient ischemic attack within 6 months prior to enrollment; New York Heart Association (NYHA) grade 3 and 4 congestive heart failure;
• Live viral vaccination within 28 days prior to the first dose of study drug;
• Unable to take oral drugs, or have severe gastrointestinal diseases that investigator believes that it may affect the absorption of the study drug;
• Insufficient compliance of patients participating in this clinical study as judged by the investigator;
• Any other disease or condition in the judgment of the investigator that the patient is not suitable for the study drug, or will affect the interpretation of the study results

Related Conditions & MeSH terms

• CLL/SLL
• NHL

Intervention

Drug:
• BN102
oral tablets: BN102, BID

Locations

Country	Name	City	State
China	ZhuJiang Hospital of Southern Medical University	Guangzhou
China	The First Affiliated School of Guangxi Medical University	Nanning
China	Shanghai Jiao Tong University School of Medicine, Ruijin Hospital	Shanghai
China	The First Affiliated Hospital of Soochow University	Suzhou
China	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan
China	Henan Oncology Hospital	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
BioNova Pharmaceuticals (Shanghai) LTD.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events and Clinical Laboratory Abnormalities	Phase1	2 year
Primary	To assess the preliminary anti-tumor activity of BN102 based on Overall response rate(ORR) assessed by the Investigator	Phase2	3 years
Secondary	Overall response rate(ORR) as assessed by the Investigator	Phase1	3 years
Secondary	Time to response(TTR) as assessed by the Investigator	Phase1/2	3 years
Secondary	Duration of response(DoR) as assessed by the Investigator	Phase1/2	3 years
Secondary	Progression-free survival(PFS) as assessed by the Investigator	Phase1/2	3 years
Secondary	Overall Survival(OS) as assessed by the Investigator	Phase1/2	3 years
Secondary	To characterized Maximum Plasma Concentration [Cmax] of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	To characterized Peak time(Tmax) of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	To characterized Clearance half-life (T1/2) of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	To characterized Area under the blood concentration-time curve (AUC0-t) of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	To characterized Clearance rate (CL/F) of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	To characterized apparent volume of distribution (Vd/F) of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	To characterized mean residence time (MRT) of BN102 by collecting and evaluating the serum at the protocol specified time points.	Phase1/2	at the end of cycle1(each cycle is28days) and Cycle2 Day1
Secondary	Number of Participants with Adverse Events and Clinical Laboratory Abnormalities	Phase2	2 years